| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Center for Blood Research, Harvard Medical School, Boston, MA 02115
C1 inhibitor (C1INH), a member of the serine proteinase inhibitor (serpin) family, is an inhibitor of proteases in the complement system, the contact system of kinin generation, and the intrinsic coagulation pathway. It is the most heavily glycosylated plasma protein, containing 13 definitively identified glycosylation sites as well as an additional 7 potential glycosylation sites. C1INH consists of two distinct domains: a serpin domain and an amino-terminal domain. The serpin domain retains all the protease-inhibitory function, while the amino-terminal domain bears most of the glycosylation sites. The present studies test the hypothesis that plasma C1INH bears sialyl Lewisx-related moieties and therefore binds to selectin adhesion molecules. We demonstrated that plasma C1INH does express sialyl Lewisx-related moieties on its N-glycan as detected using mAb HECA-452 and CSLEX1. The data also show that plasma C1INH can bind to P- and E-selectins by FACS and immunoprecipitation experiments. In a tissue culture model of endothelial-leukocyte adhesion, C1INH showed inhibition in a dose-dependent manner. Significant inhibition (>50%) was achieved at a concentration of 250 µg/ml or higher. This discovery may suggest that C1INH plays a role in the endothelial-leukocyte interaction during inflammation. It may also provide another example of the multifaceted anti-inflammatory effects of C1INH in various animal models and human diseases.
This article has been cited by other articles:
|
|
 |
|
  F. Lu, A. K. Chauhan, S. M. Fernandes, M. T. Walsh, D. D. Wagner, and A. E. Davis III The effect of C1 inhibitor on intestinal ischemia and reperfusion injury Am J Physiol Gastrointest Liver Physiol, November 1, 2008; 295(5): G1042 - G1049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice Circulation, January 1, 2008; 117(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, F. Lu, G. Qin, S. M. Fernandes, J. Li, and A. E. Davis III C1 Inhibitor-Mediated Protection from Sepsis J. Immunol., September 15, 2007; 179(6): 3966 - 3972. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Beinrohr, V. Harmat, J. Dobo, Z. Lorincz, P. Gal, and P. Zavodszky C1 Inhibitor Serpin Domain Structure Reveals the Likely Mechanism of Heparin Potentiation and Conformational Disease J. Biol. Chem., July 20, 2007; 282(29): 21100 - 21109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cai, V. S. Dole, W. Bergmeier, J. Scafidi, H. Feng, D. D. Wagner, and A. E. Davis III A Direct Role for C1 Inhibitor in Regulation of Leukocyte Adhesion J. Immunol., May 15, 2005; 174(10): 6462 - 6466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Liu, D. Zhang, J. Scafidi, X. Wu, C. C. Cramer, and A. E. Davis III C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability Blood, March 15, 2005; 105(6): 2350 - 2355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. De Simoni, E. Rossi, C. Storini, S. Pizzimenti, C. Echart, and L. Bergamaschini The Powerful Neuroprotective Action of C1-Inhibitor on Brain Ischemia-Reperfusion Injury Does Not Require C1q Am. J. Pathol., May 1, 2004; 164(5): 1857 - 1863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Lathem, T. Bergsbaken, and R. A. Welch Potentiation of C1 Esterase Inhibitor by StcE, a Metalloprotease Secreted by Escherichia coli O157:H7 J. Exp. Med., April 19, 2004; 199(8): 1077 - 1087. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
